Search research articles
Contact Us
Filters
Showing results (421-430 of 476) with videos related to
Page
of 48
Sort By:
The Journal of Antimicrobial Chemotherapy
|
June 1, 2014
Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration
Jason A Roberts, Andrew A Udy, Juergen B Bulitta, et al.
Antimicrobial Agents and Chemotherapy
|
February 23, 2023
Population Pharmacokinetics of Ganciclovir in Allogeneic Hematopoietic Stem Cell Transplant Patients
Philip R Selby, Aaron J Heffernan, David Yeung, et al.
Antimicrobial Agents and Chemotherapy
|
August 24, 2011
Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery
Alexandra Douglas, Andrew A Udy, Steven C Wallis, et al.
International Journal of Antimicrobial Agents
|
February 9, 2025
Ceftriaxone population pharmacokinetics in plasma and cerebrospinal fluid of neurocritical care patients
Nilesh Kumta, Aaron J Heffernan, Xin Liu, et al.
Antimicrobial Agents and Chemotherapy
|
August 24, 2016
Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients
Abdulaziz S Alobaid, Steven C Wallis, Paul Jarrett, et al.
Antimicrobial Agents and Chemotherapy
|
February 22, 2018
Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling
Rajbharan Yadav, Kate E Rogers, Phillip J Bergen, et al.
Antimicrobial Agents and Chemotherapy
|
January 6, 2017
Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients
Abdulaziz S Alobaid, Steven C Wallis, Paul Jarrett, et al.
The Journal of Antimicrobial Chemotherapy
|
September 10, 2024
Population pharmacokinetics of unbound cefazolin in infected hospitalized patients requiring intermittent high-flux haemodialysis: can a three-times-weekly post-dialysis dosing regimen provide optimal treatment?
Carleigh Duke, Suzanne L Parker, Betty B Zam, et al.
The Journal of Antimicrobial Chemotherapy
|
June 27, 2023
Validating a novel three-times-weekly post-hemodialysis ceftriaxone regimen in infected Indigenous Australian patients-a population pharmacokinetic study
Danny Tsai, Betty B Zam, Carleigh Tongs, et al.
Antimicrobial Agents and Chemotherapy
|
March 8, 2017
Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model
Phillip J Bergen, Jürgen B Bulitta, Carl M J Kirkpatrick, et al.
Page
of 48
Search research articles
Search
Showing results (421-430 of 476) with videos related to
Sort By:
Page
of 48
The Journal of Antimicrobial Chemotherapy
|
June 1, 2014
Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration
Jason A Roberts, Andrew A Udy, Juergen B Bulitta, et al.
Antimicrobial Agents and Chemotherapy
|
February 23, 2023
Population Pharmacokinetics of Ganciclovir in Allogeneic Hematopoietic Stem Cell Transplant Patients
Philip R Selby, Aaron J Heffernan, David Yeung, et al.
Antimicrobial Agents and Chemotherapy
|
August 24, 2011
Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery
Alexandra Douglas, Andrew A Udy, Steven C Wallis, et al.
International Journal of Antimicrobial Agents
|
February 9, 2025
Ceftriaxone population pharmacokinetics in plasma and cerebrospinal fluid of neurocritical care patients
Nilesh Kumta, Aaron J Heffernan, Xin Liu, et al.
Antimicrobial Agents and Chemotherapy
|
August 24, 2016
Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients
Abdulaziz S Alobaid, Steven C Wallis, Paul Jarrett, et al.
Antimicrobial Agents and Chemotherapy
|
February 22, 2018
Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling
Rajbharan Yadav, Kate E Rogers, Phillip J Bergen, et al.
Antimicrobial Agents and Chemotherapy
|
January 6, 2017
Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients
Abdulaziz S Alobaid, Steven C Wallis, Paul Jarrett, et al.
The Journal of Antimicrobial Chemotherapy
|
September 10, 2024
Population pharmacokinetics of unbound cefazolin in infected hospitalized patients requiring intermittent high-flux haemodialysis: can a three-times-weekly post-dialysis dosing regimen provide optimal treatment?
Carleigh Duke, Suzanne L Parker, Betty B Zam, et al.
The Journal of Antimicrobial Chemotherapy
|
June 27, 2023
Validating a novel three-times-weekly post-hemodialysis ceftriaxone regimen in infected Indigenous Australian patients-a population pharmacokinetic study
Danny Tsai, Betty B Zam, Carleigh Tongs, et al.
Antimicrobial Agents and Chemotherapy
|
March 8, 2017
Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model
Phillip J Bergen, Jürgen B Bulitta, Carl M J Kirkpatrick, et al.
Page
of 48